10 Best M&A Advisors in Indianapolis for $5M-$300M Deals (2026)

10 Best M&A Advisors in Indianapolis for $5M-$300M Deals (2026)

Quick answer: For a $5M-$150M Indiana sale, call Periculum Capital in Carmel first: it is the only firm on this list that owns its broker-dealer (Periculum Capital Markets, CRD 43362) and the only local firm with a dated 2025-26 closing record. Behind it sit two boutiques that run securities through third-party broker-dealers, EO Advisors (Zionsville) and Skellig Capital Advisors (Indianapolis), and KSM Corporate Finance, the investment-banking arm of Katz, Sapper & Miller. Above roughly $150M the bench is thin and the national banks with verified Indiana deals take over: Baird and Houlihan Lokey (lead and co-adviser on the February 2026 sale of 80/20 in Columbia City) and Lincoln International. Under about $5M, use Indiana Business Advisors, Murphy Business of Indianapolis or Transworld Business Advisors of Carmel. The one state-law fact to carry into the term sheet: Indiana taxes your gain as ordinary income at a flat 2.95% for 2026 and 2.9% for 2027 under IC 6-3-2-1, and if you sell a healthcare business above $10M of combined assets, IC 25-1-8.5 requires 90 days' notice to the Attorney General before you close.

I'm Sean Yu, co-founder of Peony, a data room company. We serve 6,800+ customers, most of them on the document side of sub-$300M transactions, and Central Indiana produces a steady share of them: founder-led manufacturers, distributors, healthcare-services groups and food-and-ag processors. I re-verified every firm in this guide in September 2026 against its own website and the SEC's adviser database, pulled the 2025-26 deal record from press releases and the firms' own news pages, and read the Indiana Code sections that change a seller's outcome. Two firms from the June 2026 edition came off the list because I could no longer verify them, and one national bank came on because it closed the largest Indiana sale of the year. Where the bench is thin, I say so.

Who are the best M&A advisors in Indianapolis?

The best Indianapolis M&A advisor for most Indiana owners is Periculum Capital, and the honest shortlist has ten names across three tiers: four Indianapolis-metro firms that run a sell-side process, three national banks with verified Indiana mandates, and three Main-Street brokerages for sub-$5M sales. Ranked by the evidence I could check, not by brochure claims:

Three notes the table cannot carry. First, "runs a process" is the test for the top four, and only one of them proves it publicly: Periculum's news page lists seven dated sell-side closings between February 2025 and June 2026, while EO Advisors, Skellig and KSM publish none. That is not disqualifying for a boutique (many sign NDAs that bar announcements), but it means you will be judging them on the team in the room and on references you call yourself. Second, the Baird, Stifel and Raymond James signs in Indianapolis belong to private-wealth branches. Baird is on this list because its Milwaukee and Chicago industrial bankers led the 80/20 sale, not because of the Meridian Street office. Third, the Main-Street tier is not FINRA-registered and does not need to be for an asset sale of a $2M business; it is the wrong tool for a $20M stock sale.

Two names from the June 2026 edition are gone. ArkMalibu, the Cincinnati sell-side firm, no longer lists an Indianapolis location anywhere on its site (its contact page names Cincinnati and New England), so I cannot call it an Indianapolis advisor; it is covered in the Cincinnati guide. American Business Investors, a Main-Street brokerage, had no reachable website in September 2026, and I do not list firms I cannot verify.

Is the Indianapolis M&A advisor bench deep enough, or should I call Chicago?

It is deep enough for a $5M-$150M generalist company and thin above that, which is the most useful single sentence in this guide. Indianapolis has one homegrown investment bank that owns its broker-dealer, two boutiques that rent one, and one CPA-affiliated corporate-finance arm. For an industrial, distribution, consumer, food-and-ag, home-services or healthcare-services business whose buyers are Midwestern strategics, family offices and lower-middle-market sponsors, that is a real bench, and Periculum's 2025-26 record (a fastener maker, a lighting brand, a building-products distributor, an ABA-therapy provider, a plumbing contractor, a pet-boarding chain) is precisely that mix.

What Indianapolis lacks is a sector desk. No Indianapolis firm published a life-sciences, medtech, software or healthcare-technology closing in 2025 or 2026. The Carmel software company OneCause was acquired by Bonterra in October 2025 without a public adviser of record. The two largest Indiana sales with a named adviser in the window, 80/20 in February 2026 and Avant Healthcare in February 2024, were run by Baird, Houlihan Lokey and Lincoln International from Milwaukee, Chicago and national sector teams. Compare the Chicago guide: Chicago has a dozen firms that would each take a $200M Indiana industrial mandate, and William Blair, Baird, Lincoln and Mesirow all keep Indiana on their coverage maps.

My routing rule, which I would apply to my own company:

• $5M-$25M, generalist sector, Midwestern buyer pool: an Indianapolis firm, with Periculum first because its record is public. Fee, attention and local relationships all favour the local boutique, and a Chicago bank will staff your deal with its most junior team.
• $25M-$150M, generalist sector: still local by default, but interview one Chicago firm to keep the local firm honest on valuation and buyer list, and expect the local firm to co-advise if the buyer list turns cross-border.
• Any size, regulated or IP-heavy niche (orthopedics, pharma services, software, gene therapy): a national sector desk, because the buyer list is specialists and the diligence is specialist. A local generalist can still add value as a co-adviser who knows the family.
• Above $150M: Chicago or a national bank leads. Indianapolis does not have a bank that has publicly run a $250M auction solo in this cycle.

The upstream version of this decision, for any city, is in the M&A advisor vs business broker vs investment bank guide.

Which Indianapolis M&A advisors closed deals in 2025 and 2026?

Periculum Capital is the only Indianapolis-based firm with a dated 2025-26 sell-side record you can check yourself, and the largest Indiana sale with a named adviser in the window went to Baird and Houlihan Lokey. Here is the ledger, restricted to transactions where a press release, the adviser's own announcement or the seller's announcement names the adviser of record; deals without one are listed without an adviser rather than guessed.

Three things the ledger tells an Indiana seller. The local record is entirely lower-middle-market and entirely generalist: fasteners, lighting, distribution, home services, behavioral health, pet care, fuel distribution. That is a compliment to Periculum's process discipline (six closings in six months across six sectors) and a warning about what the local bench does not do. The one 2026 deal that needed a national sponsor auction, 80/20, went to Baird's industrials group with Houlihan Lokey alongside, and the seller was a Cleveland private-equity firm, not an Indiana family. And the largest number on the page, Allison's $2.7B purchase of Dana's off-highway business, is an Indianapolis company buying, which matters for your buyer list, not your adviser list.

Two corrections that circulate on other lists: Periculum advised the 2018 sale of Pretzels, Inc. to Peak Rock, but the December 2021 sale of Pretzels to Hershey was advised by Evercore, so do not credit it to a local firm; and the Berry IT term-loan placement Periculum announced in December 2025 is a capital-formation mandate, not an M&A closing.

Why does Indiana's strategic-acquirer density change your buyer pool?

Because several of the most logical strategic buyers for an Indiana company are headquartered within an hour of Monument Circle, and a banker who knows their corporate-development teams personally is worth more here than in most metros this size. At least seven Indiana-headquartered public companies closed or announced material acquisitions in 2023-2026. These are buyers, never advisers, and none of them is a promise that your company is on the list.

• Eli Lilly (Indianapolis) is the spine: six acquisitions worth about $6.1B in 2023 (BioSpace, Feb 2024), Morphic for about $3.2B (announced July 8, 2024; STAT), Scorpion Therapeutics for up to $2.5B (announced January 13, 2025; Lilly IR) and Verve Therapeutics for up to about $1.3B (announced June 17, 2025; PR Newswire). Lilly buys clinical-stage biology, not Indiana service companies; its relevance to a local seller is the ecosystem of CDMOs, labs, packaging and facilities contractors its more-than-$50B U.S. manufacturing programme feeds (Lilly IR, Feb 2025).
• Allison Transmission (Indianapolis) closed its largest deal ever, Dana's Off-Highway Drive & Motion Systems business for about $2.7B, on January 1, 2026 (PR Newswire), creating a roughly $5.5B-revenue industrial with a supplier base to consolidate.
• Zimmer Biomet (Warsaw) completed Paragon 28 for about $1.1B in equity value on April 21, 2025 (PR Newswire).
• Elevance Health (Indianapolis) built out Carelon with CareBridge and Paragon Healthcare in 2024; Corteva (Indianapolis) bought Stoller for $1.2B in 2023 and announced a planned separation into two companies on October 1, 2025; Cummins (Columbus) and Steel Dynamics (Fort Wayne, which completed its purchase of the remaining 55% of New Process Steel on December 1, 2025) round out the industrial pool.

For an adviser, this density is the whole game. The screening question is not "do you know Lilly?" but "which of these corporate-development teams is buying in my category this quarter, and who is the vice president who reads the CIM?" A genuinely Indiana-fluent banker answers without hesitating and then names the fifteen to thirty sponsors that will run alongside so no strategic bids unchallenged. In the data room, that means visitor groups so strategics and sponsors see different tiers of the same file.

Who should advise a life-sciences, medtech or Warsaw orthopedics seller?

A national sector desk, with a local firm as co-adviser only if the family relationship matters. Life sciences is Indiana's dominant cluster: the sector passed $102B of economic contribution, employs about 70,000 people across 3,312 establishments at a roughly $177,000 average wage, and Indiana ranks first in the nation for life-sciences and pharma exports (Inside INdiana Business, Mar 2026). Warsaw calls itself the Orthopedic Capital of the World, home to about one-third of the world's orthopedic-device companies and two-thirds of hip and knee manufacturers (Becker's, Oct 2022).

None of that cluster shows up in the Indianapolis advisers' 2025-26 closing record. The buyers for a Warsaw component supplier, a Carmel pharma-services firm or an Indianapolis CDMO are strategics and healthcare sponsors that a sector banker already calls on, and the diligence is QA, regulatory and IP. Houlihan Lokey's healthcare and pharma-commercialization desks (its Avant Healthcare sale is the local proof point) and William Blair's healthcare group reaching in from Chicago are built for it. Where a local generalist still fits: a $5M-$30M contract manufacturer or services business whose buyer is a regional platform, where Periculum can run a tight process and pull the specialists in by name.

Two Indiana statutes reshape healthcare deals specifically, and neither appears on generic lists: the Attorney General notice requirement for healthcare transactions above $10M of combined assets and the 2023-2025 physician non-compete restrictions. Both are set out in the Indiana-law section below. On the document side, medtech diligence is where dynamic per-viewer watermarking and screenshot protection earn their keep, because the design history file and the 510(k) correspondence are the asset.

Who should advise an Indiana manufacturing or industrial seller?

For a $5M-$75M Indiana manufacturer or distributor, an Indianapolis boutique with a documented industrial record, which today means Periculum; for a $100M-plus industrial with a national sponsor pool, Baird's or Lincoln's industrials group, with Houlihan Lokey as the other 2026-proven name. Advanced manufacturing and logistics employ more than 840,000 Indiana workers, about a quarter of state jobs and 37% of output, and the sector drew a record $29B of announced investment in 2024 (CICP / Conexus, 2025).

The 2026 industrial deal record makes the split concrete. 80/20 of Columbia City, a modular T-slot framing manufacturer owned by MPE Partners, sold to Littlejohn & Co. in February 2026 with Baird as lead adviser and Houlihan Lokey as co-adviser, BakerHostetler as counsel and Forvis Mazars on financial diligence; a sponsor-to-sponsor auction of that size is a national-bank process. Aerosmith Fastening Systems, an Indiana specialty-fastener maker, sold to Spotnails the same month with Periculum as exclusive adviser; a strategic sale of a founder-owned niche manufacturer is exactly the local bank's lane.

The cycle is not uniform, and an owner timing an exit should read it honestly. StarPlus Energy, the Stellantis and Samsung SDI joint venture in Kokomo, finalized a $7.54B Department of Energy loan for two battery plants in December 2024 (DOE LPO), while the GM and Samsung SDI plant in New Carlisle paused construction in late 2025 and pushed production to 2027 as EV demand softened (Detroit News, Oct 2025). A supplier concentrated in EV programmes should expect buyers to haircut that revenue; a supplier to Allison, Cummins and the off-highway base should expect the opposite. Environmental diligence (Phase I and often Phase II site assessments, permits) is a recurring gate in a manufacturing footprint, and the sell-side due diligence prep and a structured Q&A workflow are how you keep it from stalling the back half of the schedule.

What do Indianapolis M&A advisors charge?

Indianapolis advisers price the way the U.S. lower middle market prices: a monthly retainer or fixed work fee plus a success fee at close, with the percentage falling as the deal grows. For a $25M enterprise-value sale, expect a blended success fee near 3-3.5%.

The most common structure is a Double Lehman scale: 10% of the first $1M, 8% of the second, 6% of the third, 4% of the fourth and 2% of everything above $5M. On $25M that computes to about $700,000, or 2.8%; add the uncredited portion of the retainer and any minimum-fee floor and the effective rate lands at 3-3.5%. Published surveys put the $10M-$30M band at roughly 2-5% (Eton; Firmex fee guide). Retainers in this band run about $15,000-$30,000 a month. On a $2M Main-Street sale the same Double Lehman produces $180,000, or 9%, which is why brokers rather than banks handle that band and why a broker's flat 8-12% with a $50,000-$150,000 minimum is not a rip-off, just a different business.

How it varies by tier here:

• Indianapolis firms (Periculum, EO Advisors, Skellig, KSM) run Double Lehman or a negotiated flat rate in the $10M-$75M band. Expect a minimum fee; ask whether it binds on your size.
• National banks reaching in (Baird, Houlihan Lokey, Lincoln) carry higher retainer floors and, above $100M, standard Lehman with capital-markets add-ons; the fee delta versus a local boutique is small next to the price delta a well-run auction produces.
• Main-Street brokers charge a commission on the sale price with a minimum, often payable at closing only.

Three clauses matter more than the headline rate: the base the fee applies to (enterprise value including assumed debt and earnouts, or cash at close), whether the retainer is credited against the success fee (only if the letter says so), and the tail period (banks ask for 18-24 months; cap it at 12 and narrow it to buyers the banker actually contacted). Indiana law does not regulate advisory fees. The full math and the clauses that quietly inflate the bill are in the M&A advisor fees hub.

How does Indiana tax the sale of a business, and what else in Indiana law changes a sale?

Indiana taxes your gain as ordinary adjusted gross income at a flat rate that is stepping down on a statutory schedule, has no separate capital-gains rate and no business-sale exclusion, and adds a county income tax on top; the two Indiana statutes that most change a deal are the healthcare-transaction notice law and the physician non-compete restrictions. I read the sections in September 2026 (the 2025 Indiana Code, checked against the Justia mirror because the General Assembly's site was not reachable from my network that day); confirm each with Indiana counsel.

The rate schedule, IC 6-3-2-1(b). For taxable years beginning after December 31, 2022: 3.15% for 2023; 3.05% for 2024; 3% for 2025; 2.95% for 2026; 2.9% for 2027 through 2029 (IC 6-3-2-1). The 2024-2027 steps came from HEA 1001-2023 (P.L.201-2023). P.L.80-2025 then bolted on a revenue trigger: beginning with taxable years after December 31, 2029, the rate falls another 0.05 point in each even-numbered year through 2043 if the budget agency certifies that state general-fund collections grew at least 3.5% in each of the four preceding fiscal years and are forecast to keep growing at that pace; the Department of Revenue must post each determination in a departmental notice by November 1 of the odd-numbered year. The corporate rate has been 4.9% since July 1, 2021. Local income tax is levied by county on residents at rates the counties set each year; check the Department of Revenue's county-rate list for the year of closing rather than trusting a blog, including this one.

What the step-down is worth. A gain recognized in December 2026 meets 2.95% and the same gain in January 2027 meets 2.9%: five basis points, or $5,000 of Indiana tax per $10 million of gain. That is never a reason to slip a closing across New Year's Eve; the federal rate and the buyer's financing calendar move you far more. The Nebraska and Iowa comparators in this series have larger swings; Indiana's schedule is small, flat and predictable, which is the point.

Inheritance and estate tax. Indiana repealed its inheritance tax for deaths after December 31, 2012, and has no estate tax, so the succession-planning motive for a sale is federal, not Indiana.

Healthcare-transaction notice, IC 25-1-8.5. Added by P.L.95-2024 (SEA 9), effective July 1, 2024, section 4 requires an Indiana health care entity involved in a merger or acquisition with another health care entity whose total assets, including combined entities and holdings, are at least $10 million to give the Office of the Attorney General notarized written notice at least 90 days before the transaction. The notice must describe each entity, the deal and its timeline and attach anything filed with a federal or state agency; the Attorney General reviews within 45 days, may issue a written antitrust analysis, and may serve a civil investigative demand under IC 4-6-3. "Health care entity" (section 2) reaches providers, accident-and-sickness insurers, HMOs, pharmacy benefit managers, third-party administrators and, explicitly, any private equity partnership wherever located that seeks to acquire one. The 2025 amendment (P.L.239-2025) carved out practices that are, and after closing remain, majority-owned by Indiana-licensed practitioners who routinely treat patients there. Practical effect: an ABA-therapy provider, a dental group or an infusion company selling to a sponsor-backed platform builds 90 days into the LOI-to-close calendar, and the data room's regulatory folder should hold the notice package.

Physician non-competes, IC 25-22.5-5.5. The chapter governs physician non-competes entered into on or after July 1, 2020, and section 2(a) makes one enforceable only if it contains five provisions, including patient-notice copies, patient contact information on request, record access and an option for the physician to buy a complete release at a reasonable price. Three later layers matter to a buyer:

• Since July 1, 2023 (P.L.165-2023, HEA 1004-2023), section 2(b) makes a physician non-compete unenforceable if the employer terminates without cause, the physician terminates for cause, or the contract expires with both sides having performed; section 2.5 bans non-competes with primary care physicians outright for agreements from that date; and section 2.6 forces good-faith negotiation of the buyout price, with either side able to demand mediation within 35 days and a 45-day clock to finish it.
• Since July 1, 2025 (P.L.207-2025), section 2.3 prohibits any non-compete between a physician and a hospital, a hospital's parent company, an affiliated manager or a hospital system; an agreement in violation is void.

For the seller of a physician-owned practice, the consequence is that the covenant a buyer once paid for may not exist. A hospital-system buyer cannot bind your physicians post-close at all for agreements signed after mid-2025; a sponsor-backed platform can, outside primary care, but must honour the buyout-and-mediation mechanics. Model retention with rollover equity and employment terms, not restrictive covenants, and expect the buyer's counsel to reprice accordingly.

Securities registration for the intermediary. A stock sale is a securities transaction. The federal M&A-broker exemption in Exchange Act section 15(b)(13) (effective March 29, 2023) lets an unregistered intermediary handle a private-company stock sale only when the target had under $25M of EBITDA or under $250M of revenue in the prior fiscal year (Jones Day, Jan 2023), and it does not preempt state law. The Indiana Securities Division takes its own position on M&A-broker registration, so confirm the current one before relying on the federal exemption; the practical rule is to ask which FINRA member carries the transaction and to check it on BrokerCheck rather than assume the federal exemption cleared the firm in Indiana.

Marital property. Indiana is an equitable-distribution state, not a community-property state, so a spouse's signature is not a statutory condition of a sale the way it is in Texas; the buyer's counsel may still ask for a spousal consent as belt-and-braces.

Which firms should I not mistake for an M&A advisor in Indianapolis?

Several well-known Indiana names get listed as M&A advisers and are not, and the mistake costs sellers months. Getting this right is half of vetting the market.

• Centerfield Capital Partners is a mezzanine and equity fund and Cardinal Equity Partners is a private-equity buyer; both are counterparties, not advisers.
• Goelzer Investment Management is a registered investment adviser managing wealth, not a broker-dealer running deals.
• Cambridge Capital Management is an SBA 504 lender; Pearl Street Venture Funds and Springboard Capital are venture funds; Telamon is a technology and staffing company.
• The in-state strategics above (Lilly, Elevance, Cummins, Allison, Zimmer Biomet, Corteva, Steel Dynamics) are buyers and never advisers.
• The Indianapolis offices of Baird, Stifel and Raymond James are private-wealth branches. Baird earns its place on this list through its Milwaukee and Chicago industrials bankers, not through the Meridian Street office.
• ArkMalibu is a real sell-side firm, headquartered in Cincinnati with locations it describes as New England; its site no longer shows an Indianapolis office, so treat it as an out-of-state adviser that can reach in.
• Search-engine "business brokers" with no verifiable Indiana office, team page or closings do not belong on a shortlist regardless of how many city pages they publish.

The reliable filter for any name: is a FINRA member (its own or a third party's) carrying the securities transaction, does the firm run sell-side processes rather than invest its own capital or manage wealth, and can it name a dated closing in your band? Three yeses or it is not an adviser.

How do I verify an Indianapolis M&A advisor before I sign?

Check the broker-dealer, the dated closings and the staffing commitment, in that order, and treat the pitch as the least reliable signal in the room. In Indianapolis the broker-dealer check is unusually easy because there are only three answers: Periculum Capital Markets (CRD 43362, the firm's own), M&A Securities Group of Kansas City (carries EO Advisors and KSM Corporate Finance) and Kittle Capital Markets of Indianapolis (carries Skellig's Bob Welch). Look each up on BrokerCheck and confirm the individual banker is a registered representative of it. A Main-Street broker will not be on BrokerCheck and does not need to be for an asset sale; ask instead for IBBA or M&A Source credentials and for a list of businesses sold.

For closings, ask for the last three deals in your sub-sector with the buyer named and a reference at each, then read the announcements yourself. Periculum's news page is the local benchmark; a firm that publishes nothing should be able to hand you a redacted tombstone list and two owners who will take your call. For staffing, get the name of the senior banker who will be on every buyer call written into the engagement letter, because the bait-and-switch to a vice president is the most common complaint I hear from sellers after the fact.

Red flags: a valuation that wins the mandate with no comparable transactions behind it; a large upfront fee with a vague success structure; a refusal to negotiate the tail; and an adviser who proposes to email your financials to buyers instead of using a permissioned data room. That last one tells you how the rest of the process will be run.

Which data room should an Indianapolis seller use, and do I need one?

You need one for any sale above the Main-Street band, and in a market this small the reason is confidentiality before it is convenience. The buyers for a Central Indiana company are often an hour's drive away; a leaked teaser reaches a competitor, a key customer or your plant manager in a week, and the damage lands before the LOI does.

Three controls do the work: staged disclosure (a blind teaser, then an NDA, then the named CIM, then the sensitive tier of customer names, pricing and employee rosters for a short list only), dynamic per-viewer watermarks so a leaked page carries the leaker's identity, and page-level analytics so you and the banker can see which buyers are actually reading and which are logo-collecting. Put a do-not-contact list of competitors in the engagement letter and make the room enforce it.

On vendor choice: Datasite and Intralinks are built for $500M-plus processes with pre-existing law-firm and R&W-underwriter relationships, and they price accordingly. For the sub-$300M band that is almost every Indiana deal, I run Peony, a data room company used by 6,800+ customers (G2 4.8, Capterra 4.9), priced flat per admin with no per-page or per-gigabyte fees: Free at $0, Business at $30, Data Room at $52 and Deal Team at $64 per admin per month billed annually. Watermarks, page-level analytics and visitor groups for a strategics-versus-sponsors split live on the Data Room tier; screenshot protection starts on Business. The setup playbook, workstream by workstream, is in the M&A data room guide, and the sub-$30M version is in best data room for a small M&A deal.

What is the bottom line for an Indiana seller?

Indianapolis is one of the few secondary metros that does not have to ship every meaningful deal to Chicago, because Periculum Capital in Carmel is a real in-state investment bank with a public 2025-26 closing record, and EO Advisors, Skellig and KSM give a $5M-$150M generalist seller a genuine second and third call. Above $150M, in a regulated or IP-heavy niche, or with a cross-border buyer list, the bench is thin and the honest plan is a national bank with an Indiana track record (Baird, Houlihan Lokey, Lincoln International), possibly with a local firm as co-adviser. Under $5M, use a Main-Street broker and keep the bank's minimum fee in your pocket.

Carry three Indiana facts into the process: the state takes a flat 2.95% of your gain in 2026 and 2.9% in 2027, a healthcare deal above $10M of combined assets owes the Attorney General 90 days' notice, and a physician non-compete signed after mid-2023 is worth less than a buyer's model assumes. And do the preparation that compounds everything the adviser does next: clean financials, a quality-of-earnings file, a tight buyer thesis and a staged, watermarked data room set up before the first buyer call. We serve 6,800+ customers on exactly that side of these deals, and the sellers who prepare before they pick the banker are the ones who get to choose the buyer instead of taking the one that showed up.

Frequently asked questions about Indianapolis M&A advisors

Who are the best M&A advisors in Indianapolis?

For a $5M-$150M Indiana sell-side, start with Periculum Capital in Carmel, the only firm on this list that owns its broker-dealer (Periculum Capital Markets, CRD 43362) and a dated 2025-26 closing record (Barkefellers, Aerosmith Fastening, Good Earth Lighting, Dealers Wholesale, Cornerstone Autism Center). Next come two boutiques that run deals through third-party broker-dealers: EO Advisors in Zionsville (established 2021, securities through M&A Securities Group) and Skellig Capital Advisors in Indianapolis (Bob Welch, $25M to $1B mandates, securities through Kittle Capital Markets), plus KSM Corporate Finance, the investment-banking arm of the Indianapolis CPA firm Katz, Sapper & Miller. Above roughly $150M, national banks reach in with verified Indiana mandates: Baird (lead adviser on the February 2026 sale of 80/20 in Columbia City), Houlihan Lokey (co-adviser on 80/20; sell-side to Avant Healthcare of Carmel in 2024) and Lincoln International (Wellness Pet's Mishawaka plant, 2024). Under about $5M, the Main-Street bench is Indiana Business Advisors (since 1981), Murphy Business of Indianapolis and Transworld Business Advisors of Carmel.

Is the Indianapolis M&A advisor bench deep enough, or should I call Chicago?

It is deep enough for a $5M-$150M generalist sale and thin above that. Indianapolis has one homegrown investment bank that owns its broker-dealer (Periculum), two boutiques that rent one (EO Advisors, Skellig) and one CPA-affiliated corporate-finance arm (KSM), which is a real bench for the industrial, distribution, consumer, food-and-ag and healthcare-services companies that make up most Indiana deal count. What it does not have is a Chicago-scale sector desk: no Indianapolis firm published a life-sciences, medtech or software closing in 2025-26, and the two largest Indiana sales with a named adviser in that window (80/20, February 2026, and Avant Healthcare, 2024) were run by Baird, Houlihan Lokey and Lincoln International from outside the state. The Baird, Stifel and Raymond James offices in Indianapolis are wealth-management branches, not deal teams. My rule: call a local firm first for a sub-$150M generalist company whose buyers are Midwestern strategics and sponsors; call Chicago or a national sector desk when the deal is above $150M, cross-border, or in a regulated or IP-heavy niche where the buyer list is specialists.

What do Indianapolis M&A advisors charge?

The same way the rest of the U.S. lower middle market charges: a monthly retainer plus a success fee at close, with the percentage falling as the deal grows. On a $25M Indiana sale, a Double Lehman scale (10% of the first $1M, 8% of the second, 6% of the third, 4% of the fourth, 2% above $5M) computes to about $700,000, or 2.8%; add the uncredited part of a $15,000-$30,000 monthly retainer and any minimum-fee floor and the blended rate lands near 3-3.5%. Published surveys put the $10M-$30M band at roughly 2-5%. Main-Street brokers on sub-$5M sales usually charge a flat 8-12% or a Double Lehman where the minimum fee (often $50,000-$150,000) dominates, which is why a FINRA bank rarely takes a $3M mandate. Three clauses matter more than the headline rate: the base the fee applies to (enterprise value including assumed debt and earnouts, or cash at close), whether the retainer is credited against the success fee, and the tail period (banks ask for 18-24 months; cap it at 12). Indiana law does not regulate M&A advisory fees; the engagement letter does.

How does Indiana tax the sale of a business?

Indiana taxes the gain as ordinary adjusted gross income at a flat rate that is stepping down on a statutory schedule in IC 6-3-2-1: 3.05% for 2024, 3% for 2025, 2.95% for taxable years beginning in 2026, and 2.9% for 2027 through 2029, with conditional 0.05-point cuts in even years from 2030 if state general-fund revenue grows at least 3.5% a year (the schedule was set by HEA 1001-2023 and extended by P.L.80-2025). There is no separate capital-gains rate and no exclusion for the sale of a business; on top of the state rate, Indiana counties levy a local income tax on residents (Marion County's rate is set annually by the county, so check the Department of Revenue's county-rate list for the year you close). Indiana has no inheritance tax (repealed for deaths after December 31, 2012) and no estate tax. A gain recognized in December 2026 meets 2.95% and the same gain in January 2027 meets 2.9%: $5,000 of Indiana tax per $10 million of gain, which is rarely a reason to slip a closing. Confirm the county rate and any nonresident-seller mechanics with an Indiana tax adviser; the statute text above was checked in September 2026.

Should I hire a local Indianapolis boutique or a national investment bank for a $25M manufacturing sale?

For a $25M Indiana manufacturer, a local boutique is the right default. Price comes from competitive tension, not from the banker's zip code, and a $25M industrial company's buyers are Midwestern strategics, family offices and lower-middle-market sponsors that Periculum, EO Advisors and Skellig already call on. Periculum's 2026 closings (Aerosmith Fastening to Spotnails, Dealers Wholesale to Lacy Diversified Industries) are exactly this profile. Reach for a national bank when the buyer pool is cross-border, the sub-sector needs a specialist desk, or the deal is above roughly $150M, where Baird, Houlihan Lokey and Lincoln International have the Indiana track record. Either way, the prep is the same: clean financials, a quality-of-earnings file and a staged data room before launch. I run Peony, a data room company used by 6,800+ customers, and the sellers who set the room up before the banker's first buyer call consistently close faster than the ones who scramble after the LOI.

Which Indianapolis M&A advisors actually closed deals in 2025 and 2026?

Periculum Capital has the only Indianapolis-based 2025-26 sell-side record you can check on the firm's own news page: Barkefellers to Destination Pet (June 23, 2026), Aerosmith Fastening Systems to Spotnails (February 24, 2026), Good Earth Lighting to Feit Electric (February 10, 2026), Dealers Wholesale to Lacy Diversified Industries (January 22, 2026), Cornerstone Autism Center to LEARN Behavioral (January 5, 2026), BOC Oil to Cadence Petroleum (January 13, 2026; the seller is a South Carolina company) and the Hope Plumbing recapitalization by Redwood Services (February 24, 2025). The largest Indiana sale with a named adviser in the window was 80/20 of Columbia City, sold by MPE Partners to Littlejohn & Co. (announced February 3, 2026) with Baird as lead financial adviser and Houlihan Lokey as co-adviser. EO Advisors, Skellig and KSM Corporate Finance publish no dated, named 2025-26 Indiana closings; judge them on team and pedigree, and ask for references.

Do I need an investment banker, or will a business broker do for my Indiana company?

Deal size decides it. Under about $5M of enterprise value, a Main-Street business broker (Indiana Business Advisors, Murphy Business of Indianapolis, Transworld Business Advisors of Carmel) is the right call: the buyer is usually an individual or a small strategic, the marketing runs through listing networks, and a FINRA bank's minimum fee would eat the proceeds. From $5M to about $150M you want a firm that runs a competitive process with a senior banker on every buyer call (Periculum, EO Advisors, Skellig, KSM). Above $150M you add a national bank. The licensing line matters: a sale of stock is a securities transaction, and the federal M&A-broker exemption in Exchange Act section 15(b)(13) (effective March 29, 2023) covers unregistered intermediaries only when the target had under $25M of EBITDA or under $250M of revenue in the prior fiscal year, and it does not preempt Indiana's own registration rules. Ask any intermediary which broker-dealer carries the transaction and check it on BrokerCheck.

How do Indiana's physician non-compete rules affect the sale of a medical practice?

They can remove the covenant a buyer is paying for, so price them in before you go to market. IC 25-22.5-5.5 applies to physician non-competes entered into on or after July 1, 2020, and requires five provisions for one to be enforceable, including a buyout option at a reasonable price. Since July 1, 2023 (P.L.165-2023), a physician non-compete is unenforceable if the employer terminates without cause, the physician terminates for cause, or the contract expires with both sides having performed, and primary-care physicians cannot sign a non-compete at all. Since July 1, 2025 (P.L.207-2025, section 2.3), a physician may not enter a non-compete with a hospital, a hospital's parent, an affiliated manager or a hospital system; any such agreement is void. A hospital-system buyer therefore cannot bind your physicians post-close the way a 2022 buyer could, and a PE-backed platform buyer still faces the primary-care ban and the buyout-and-mediation mechanics in section 2.6. Model retention with employment terms and equity, not covenants.

Does Indiana require notice to the Attorney General before a healthcare deal closes?

Yes, for deals above a $10M asset threshold. Under IC 25-1-8.5-4 (added by P.L.95-2024, effective July 1, 2024), an Indiana health care entity involved in a merger or acquisition with another health care entity whose total assets, including combined entities and holdings, are at least $10 million must give the Office of the Attorney General notarized written notice at least 90 days before the transaction, including a description of the deal, its timeline and copies of anything filed with federal or state agencies. The Attorney General reviews within 45 days, may issue a written antitrust analysis, and may serve a civil investigative demand for more information. Health care entity is defined broadly (providers, insurers, HMOs, pharmacy benefit managers, third-party administrators, and any private equity partnership, wherever located, acquiring one); a practice that is, and after closing remains, majority-owned by Indiana-licensed practitioners who routinely treat patients there is excluded (P.L.239-2025). Build the 90 days into the timeline between LOI and close.

Which data room should an Indianapolis seller use, and does it matter?

It matters more in a small market than a large one, because confidentiality is the thing an Indiana seller loses first. The buyers for a Central Indiana company are often an hour's drive away, and a leaked teaser can reach a competitor, a key customer or your plant manager in a week. Three controls do the work: staged disclosure (blind teaser, NDA, then the CIM, then the sensitive tier only for a short list), dynamic per-viewer watermarks so any leaked page carries the leaker's identity, and page-level analytics so you and the banker can see which buyers are actually reading. Datasite and Intralinks are built for $500M-plus processes and price accordingly; for the sub-$300M band that is almost every Indiana deal, I run Peony, a data room company used by 6,800+ customers (G2 4.8, Capterra 4.9), priced flat per admin: Free at $0, Business at $30, Data Room at $52 and Deal Team at $64 per admin per month billed annually, with no per-page or per-gigabyte fees. Watermarks and visitor groups for a strategics-versus-sponsors split live on the Data Room tier; screenshot protection starts on Business.

How do I verify an Indianapolis M&A advisor before signing an engagement letter?

Check three things and treat the pitch as the least reliable signal. First, the broker-dealer: a securities-based sale should run through a FINRA member you can find on BrokerCheck (Periculum Capital Markets, CRD 43362; M&A Securities Group for EO Advisors and KSM Corporate Finance; Kittle Capital Markets for Skellig). Second, dated closings in your sub-sector with the buyer named, on the firm's own site or in a press release, not a logo wall; Periculum's news page is the local standard. Third, a written staffing commitment naming the senior banker who will be on your buyer calls. Red flags: a valuation that wins the mandate but no comparable transactions behind it, a large upfront fee with a vague success structure, a refusal to negotiate the 18-24 month tail, and an adviser who emails your financials instead of using a permissioned data room. For an Indiana seller, add one test: can the banker name the in-state strategics and the last deal each closed in your category?

Can a local Indianapolis boutique reach strategic buyers like Eli Lilly, Elevance or Cummins?

Reaching them is easy; being wanted by them is the question. Indiana has an unusually dense in-state pool of acquisitive public companies for a non-coastal state: Eli Lilly, Elevance Health, Cummins, Allison Transmission (which closed its roughly $2.7B purchase of Dana's Off-Highway business on January 1, 2026), Zimmer Biomet in Warsaw, Corteva and Steel Dynamics. These are corporate-development teams with specific theses, not a shopping list for every Indiana company, and a $20M supplier is far more likely to sell to a Midwestern sponsor or a mid-cap strategic than to Lilly. A good local banker's job is to know which corporate-development team is buying in your category this quarter and to get the CIM to the right vice president, then to run 15-30 named sponsors alongside so no strategic bids unchallenged. Ask for that list before you sign. Visitor groups in the data room let you run the strategics and the sponsors as separate permissioned tiers so each sees only its stage.

How long does a lower-middle-market Indiana sale take from engagement to close?

Six to nine months is typical, longer if the financials need cleanup and longer again if a healthcare buyer must give the Attorney General 90 days' notice under IC 25-1-8.5. The rough sequence: four to eight weeks of preparation (quality-of-earnings, CIM, data room), two to four weeks of outreach under NDA from a blind teaser, three to five weeks to collect indications of interest, four to six weeks of management meetings and LOI negotiation, then eight to twelve weeks of confirmatory diligence and definitive-agreement drafting. Manufacturing deals add environmental diligence (Phase I and often Phase II site assessments) and medtech deals add QA and regulatory review, and both go faster when the data room is populated before launch rather than after the first LOI. The single biggest schedule risk is walking into market without auditable numbers.

Related resources

• Best M&A Advisors: the 43-city and 15-sector directory, the national hub this guide belongs to
• M&A advisor vs business broker vs investment bank, the decision that comes before this shortlist
• M&A advisor fees: what you actually pay, Lehman and Double Lehman math, retainer credits, minimum fees and tails
• M&A due diligence: 6-phase playbook and 8 workstreams, what the buyer is doing after the LOI
• M&A data room: setup and workstream mapping, the sell-side prep playbook
• Best data room for a small M&A deal, the sub-$30M version
• Sell-side due diligence: the 90-day prep pyramid, vendor DD for manufacturing and medtech footprints
• How to write a CIM, the offering document your adviser will build
• Best M&A Advisors in Chicago, the desk most Indiana $150M-plus mandates end up on
• Best M&A Advisors in Cincinnati, where ArkMalibu is covered
• Best M&A Advisors in Columbus, the neighbouring metro whose boutiques also rent third-party broker-dealers
• Best M&A Advisors in St. Louis, the closest headquarters-town comparator with a homegrown bank
• Best M&A Advisors in Omaha and Des Moines, the other Midwest guides in this series with state-tax schedules by effective year
• Best M&A Advisors in Kansas City, home of the Animal Health Corridor that Elanco anchors from Greenfield

Footnotes and sources

• Periculum Capital, news page: dated sell-side announcements Feb 2025-Jun 2026 (Barkefellers, Aerosmith Fastening, Good Earth Lighting, Dealers Wholesale, BOC Oil, Cornerstone Autism Center, Hope Plumbing, Prairie Mills); footer disclosure that securities run through Periculum Capital Markets, LLC, Member FINRA/SIPC; SEC adviser search returns Periculum Capital Markets, CRD 43362
• EO Advisors: established 2021; Zionsville and Newtown Square offices; securities through M&A Securities Group, Inc., Member FINRA/SIPC
• Skellig Capital Advisors: Robert V. Welch Jr., CEO; $25M-$1B Midwestern mandates; registered representative of Kittle Capital Markets, LLC, Indianapolis
• KSM (Katz, Sapper & Miller): site disclosure that broker-dealer services are offered through M&A Securities Group, Inc., a separate entity from KSM Corporate Finance
• ArkMalibu: contact page lists Cincinnati headquarters and New England locations; no Indianapolis office shown (checked September 2026)
• Indiana Business Advisors: Main Street and lower-middle-market brokerage since 1981, 9333 N. Meridian St., Indianapolis
• Murphy Business of Indianapolis and Transworld Business Advisors of Carmel: office pages
• MPE Partners completes sale of 80/20 to Littlejohn & Co., Feb 3, 2026: Baird lead financial adviser, Houlihan Lokey co-adviser, BakerHostetler counsel, Forvis Mazars financial due diligence; also listed on MPE Partners news
• Lincoln International, transaction page: Wellness Pet Company engaged Lincoln as exclusive financial adviser on the Mishawaka plant sale to United Petfood, June 2024
• Houlihan Lokey, transaction page: exclusive financial adviser to Avant Healthcare (Carmel) on its sale to Real Chemistry, closed February 1, 2024; adviser also named in the Business Wire release
• IC 6-3-2-1, individual adjusted gross income tax rate schedule (2025 Indiana Code; P.L.201-2023 and P.L.80-2025)
• IC 25-1-8.5, reporting of health care entity mergers and acquisitions (P.L.95-2024; P.L.239-2025)
• IC 25-22.5-5.5, physician noncompete agreements (P.L.93-2020; P.L.165-2023; P.L.207-2025)
• Jones Day, federal M&A broker exemption and Indiana Securities Division
• Allison Transmission completes Dana Off-Highway acquisition (PR Newswire, January 2026)
• Zimmer Biomet completes Paragon 28 (PR Newswire, April 2025)
• Eli Lilly Q4 2023 results, Morphic, Scorpion, Verve, U.S. manufacturing investment
• BioCrossroads life-sciences impact (Inside INdiana Business, March 2026); Warsaw orthopedics cluster (Becker's, October 2022)
• Conexus / CICP advanced-manufacturing investment; DOE loan to StarPlus Energy; GM and Samsung SDI New Carlisle pause
• Eton, M&A advisory fees by deal size; Firmex M&A fee guide